基线血Oncostatin M水平对肾动脉狭窄患者新发心血管事件的预测价值

• 投稿 • 下一篇

基线血Oncostatin M水平对肾动脉狭窄患者新发心血管事件的预测价值

谢木金,任莎卡,刘露,李海玲,徐思玲,车文良

上海市徐汇区凌云社区卫生服务中心,同济大学附属第十人民医院心内科,同济大学附属第十人民医院心内科,同济大学附属第十人民医院心内科,同济大学附属第十人民医院心内科,同济大学附属第十人民医院心内科

收稿日期:2017-10-24 修回日期:2017-11-02 出版日期:2017-11-25
基金资助:
上海市医学引导项目（项目编号：124119a6900；项目名称：肾动脉狭窄加速性动脉粥样硬化相关炎性因子及其对心血管不良事件的预测价值）；国家自然科学基金（项目编号：81570436；项目名称：Oncostatin M在肾动脉狭窄加速动脉粥样硬化中的作用及机制研究）

Predictive Value of Baseline Blood Oncostatin M Levels on Major Adverse Cardiovascular Events in Patients with Renal Artery Stenosis

xiemujin,Ranshaka Auckle,liulu,lihailing,xusiling and chewenliang

Lingyun Community Health Service Center of Xuhui District,Tenth Hospital, Tongji University School of Medicine,Tenth Hospital, Tongji University School of Medicine,Tenth Hospital, Tongji University School of Medicine,Tenth Hospital, Tongji University School of Medicine,Tenth Hospital, Tongji University School of Medicine

Received:2017-10-24 Revised:2017-11-02 Online:2017-11-25

摘要/Abstract

摘要： 目的：检测肾动脉狭窄（RAS）患者血Oncostatin M(OSM)基线水平并探讨其对心血管事件的预测价值。方法：790例拟诊冠心病患者行冠状动脉造影同时行肾动脉造影术，获取资料、检测血OSM水平并随访12个月，观察随访期间新发生的主要不良心脏事件（MACE）。结果：122例（15.4%）患者存在≥50%的RAS，其中狭窄≥75%为31例（3.9%），50%~74%为91例（11.5%）。RAS患者高血压、高血脂及冠脉3支病变比例升高，年龄、收缩压、舒张压、血清同型半胱氨酸(Hcy)以及OSM水平显著高于无RAS患者。多变量Logistic回归分析显示，除年龄、高血压及冠脉3支病变外，基线血清OSM水平为RAS的独立危险因素。基线血清OSM水平较高的患者因心脏事件再次入院的比例显著升高（25.7% vs 5.8%，P=0.008）。多因素分析显示，矫正混杂因素后，基线血清OSM水平与MACE相关（HR=1.189， 95% CI为1.117~1.264，P＜0.05）。结论：RAS患者血清OSM水平显著升高，为RAS的独立危险因素，基线血OSM水平与RAS患者新发心血管不良事件相关。

Abstract: Objective：To investigate baseline blood OSM levels and assess its predictive value on major adverse cardiovascular events in patients with renal artery stenosis(RAS).Methods： Datas of seven hundred and ninety patients with coronary heart disease underwent both coronary angiography and renal arteriography were collected，blood OSM levels assessed and patients were followed up for a period of 12 months for any new occurrence of major adverse cardiovascular events(MACE).Results： Of the 122 patients with ≥50% stenosis of the renal artery， 31 patients(3.9%) had ≥75% stenosis while 91 patients(11.5%) had stenosis between 50%~74%. The rate of hypertension， hyperlipidemia and triple vessel disease was higher in RAS patients. RAS patients were also found to be older with higher systolic and diastolic blood pressure， higher serum OSM homocysteine(Hcy) and OSM levels compared to those without RAS. Multivariate Logistic regression analysis showed that baseline serum OSM levels were independent risk factors for RAS in addition to age， hypertension and triple vessel disease. Patients with higher baseline serum levels had significantly higher occurrence of cardiovascular related hospitalization (25.7% vs 5.8%， P=0.008）. Multivariate analysis showed that baseline serum OSM levels were correlated with MACE after adjusting for confounding factors（HR=1.189，95% CI：1.117~1.264， P<0.05）. Conclusion： Serum OSM levels are significantly elevated in RAS patients and can be considered as an independent factor for RAS. Baseline serum OSM levels are associated with occurrence of new MACE in RAS patients.

谢木金,任莎卡,刘露,李海玲,徐思玲,车文良. 基线血Oncostatin M水平对肾动脉狭窄患者新发心血管事件的预测价值[J]. .

xiemujin,Ranshaka Auckle,liulu,lihailing,xusiling and chewenliang. Predictive Value of Baseline Blood Oncostatin M Levels on Major Adverse Cardiovascular Events in Patients with Renal Artery Stenosis[J]. .

参考文献

[1] Safian R D, Textor S C. Renal-artery stenosis[J]. N Engl J Med, 2001,344(6):431-442.
[2] Hansen K J, Edwards M S, Craven TE, et al. Prevalence of renovascular disease in the elderly: a population-based study[J]. J Vasc Surg,2002,36(3):443-451.
[3] Bernard C, Merval R, Lebret M, et al. Oncostatin M induces interleukin-6 and cyclooxygenase-2 expression in human vascular smooth muscle cells : synergy with interleukin-1beta[J]. Circ Res,1999,85(12):1124-1131.
[4] Wang Y, Ho D S, Chen W H, et al. Prevalence and predictors of renal artery stenosis in Chinese patients with coronary artery disease[J]. Intern Med J, 2003,33(7):280-285.
[5] Demyanets S, Kaun C, Rychli K, et al. Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-gamma[J]. Basic Res Cardiol, 2011,106(2):217-231.
[6] Rychli K, Kaun C, Hohensinner P J, et al. The inflammatory mediator oncostatin M induces angiopoietin 2 expression in endothelial cells in vitro and in vivo[J]. J Thromb Haemost,2010,8(3):596-604.
[7] Nishibe T, Parry G, Ishida A, et al. Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: evidence for Erk-1/2 activation[J]. Blood, 2001,97(3):692-699.
[8] Nagata T, Kai H, Shibata R, et al. Oncostatin M, an interleukin-6 family cytokine, upregulates matrix metalloproteinase-9 through the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cultured smooth muscle cells[J]. Arterioscler Thromb Vasc Biol,2003,23(4):588-593.
[9] Conlon P J, Athirakul K, Kovalik E, et al. Survival in renal vascular disease[J]. J Am Soc Nephrol,1998,9(2):252-256.
[10] Conlon P J, Little M A, Pieper K, et al. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography[J]. Kidney Int, 2001,60(4):1490-1497.
[11] Harding M B, Smith L R, Himmelstein S I, et al. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization[J]. J Am Soc Nephrol,1992,2(11):1608-1616.
[12] Rihal C S, Textor S C, Breen J F, et al. Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography[J]. Mayo Clin Proc,2002,77(4):309-316.
[13] 王芳, 王梅, 王海燕. 动脉粥样硬化患者肾动脉狭窄患病率的调查[J]. 中华肾脏病杂志,2005,21(03):139-142.
[14] 陈津, 周颖玲, 罗德谋等. 肾动脉狭窄大鼠模型的心脏结构及微循环改变[J]. 岭南心血管病杂志, 2015(04):539-543.
[15] Nicoletti A, Heudes D, Mandet C, et al. Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats[J]. Cardiovasc Res,1996,32(6):1096-1107.
[16] Chade A R, Rodriguez-Porcel M, Herrmann J, et al. Antioxidant intervention blunts renal injury in experimental renovascular disease[J]. J Am Soc Nephrol. 2004,15(4):958-966.
[17] Stouffer G A, Pathak A, Rojas M. Unilateral renal artery stenosis causes a chronic vascular inflammatory response in ApoE-/- mice[J]. Trans Am Clin Climatol Assoc,2010,121:252-264; 264-266.
[18] Kastl S P, Speidl W S, Katsaros K M, et al. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation[J]. Blood,2009,114(13):2812-2818.
[19] Zhang X, Zhu D, Wei L, et al. OSM Enhances Angiogenesis and Improves Cardiac Function after Myocardial Infarction[J]. Biomed Res Int,2015,2015:317905.
[20] Li X, Zhang X, Wei L, et al. Relationship between serum oncostatin M levels and degree of coronary stenosis in patients with coronary artery disease[J]. Clin Lab, 2014,60(1):113-118.

快速检索引用检索图表检索高级检索